Search
Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled
Zileuton
go.drugbank.com/drugs/DB00744ApprovedWithdrawnThe immediate release tablet of Zileuton has been withdrawn from the US market. … Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigationalSelinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. … [L10145] The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at
Narsoplimab
go.drugbank.com/drugs/DB16418ApprovedInvestigational[A241045, A241050] Approved by the FDA on December 24, 2025, narsoplimab-wuug is indicated for the treatment of hematopoietic stem cell transplant–associated thrombotic microangiopathy (TA-TMA) in adults … [A241030] Evidence increasingly points to a role for the complement system in TMA.
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . … The same dosing regimen in treatment-naïve patients with HCV genotype 3 infection with or without cirrhosis achieved SVR12 rates of 71% and 98%, respectively [FDA Label].
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTetracycline
go.drugbank.com/drugs/DB00759ApprovedInvestigationalVet approvedWithdrawnIt exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. … The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml.
Categories: Antibiotics for Topical Use, Antibacterials for Systemic UseProducts: TETRACICLINA MK CLORHIDRATO 500MG CAPSULASRifampin
go.drugbank.com/drugs/DB01045ApprovedInvestigational[A263768] Rifampin is used to treat tuberculosis and works by inhibiting the microbial DNA-dependent RNA polymerase (RNAP).[A263768]
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of LepraEquine Botulinum Neurotoxin F Immune FAB2
go.drugbank.com/drugs/DB13901ApprovedIt is intravenously administered for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes F in adults and pediatric patients. … Equine Botulinum Neurotoxin F Immune FAB2 is composed of a mixture of immune globulin fragments purified from plasma of horses that were previously immunized with botulinum toxin serotype F.
XPro1595
go.drugbank.com/drugs/DB16454InvestigationalXPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.
Synonyms: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.Categories: Experimental Unapproved Treatments for COVID-19Difelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[L36420,L36395] Difelikefalin was later approved by the EMA in April 2022 for the same indication.[L41665] … [A237620] Difelikefalin received FDA approval in August 2021 (under the brand name Korsuva), becoming the first FDA-approved therapy for patients with chronic kidney disease suffering from uremic pruritus